Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α

Oncogene

Volumn 31, Issue 27, 2012, Pages 3223-3234

  Vesuna, F ^a   Lisok, A ^a   Kimble, B ^a   Domek, J ^a   Kato, Y ^a   Van Der Groep, P ^b   Artemov, D ^a   Kowalski, J ^c   Carraway, H ^c   Van Diest, P ^b   Raman, V ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

breast cancer; ER transcriptional regulation; histone deacetylation; hormone resistance; methylation; Twist

Indexed keywords

AZACITIDINE; DNA METHYLTRANSFERASE 3B; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HISTONE DEACETYLASE 1; TAMOXIFEN; TRANSCRIPTION FACTOR TWIST; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DEACETYLATION; DRUG EFFECT; E BOX ELEMENT; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; BREAST NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CHROMATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; E-BOX ELEMENTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HISTONE DEACETYLASE 1; HISTONES; HUMANS; MICE; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; RNA, SMALL INTERFERING; TAMOXIFEN; TWIST TRANSCRIPTION FACTOR; VALPROIC ACID;

MUS;

EID: 84863725383     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.483     Document Type: Article

References (40)

1. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. (2004). Regulation of estrogen receptoralpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180: 497-504. (Pubitemid 38443401)
2. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. (2001). Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3: 143-153. (Pubitemid 32410355)
3. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N et al. (2004). A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423-435. (Pubitemid 38364573)
4. Bikfalvi A, Bicknell R. (2002). Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 23: 576-582. (Pubitemid 35375803)
5. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107. (Pubitemid 29036293)
6. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. (2001). Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824.
7. Cho EY, Choi YL, Chae SW, Sohn JH, Ahn GH. (2006). Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms. Int J Gynecol Cancer 16: 1000-1006. (Pubitemid 43886717)
8. deConinck EC, McPherson LA, Weigel RJ. (1995). Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 15: 2191-2196.
9. deGraffenried LA, Hilsenbeck SG, Fuqua SA. (2002). Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol 82: 7-18. (Pubitemid 35341397)
10. El Ghouzzi V, Legeai-Mallet L, Aresta S, Benoist C, Munnich A, de Gunzburg J et al. (2000). Saethre-Chotzen mutations cause TWIST protein degradation or impaired nuclear location. Hum Mol Genet 9: 813-819. (Pubitemid 30162766)
11. Foster JS, Wimalasena J. (1996). Estrogen regulates activity of cyclindependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10: 488-498. (Pubitemid 26142575)
12. Fox MH. (1980). A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. Cytometry 1: 71-77.
13. Fuqua SA,Wiltschke C, Zhang QX, Borg A, Castles CG, FriedrichsWE et al. (2000). A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60: 4026-4029. (Pubitemid 30636577)
14. Harvey JM, Clark GM, Osborne CK, Allred DC. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481. (Pubitemid 29220854)
15. Hebrok M, Fuchtbauer A, Fuchtbauer EM. (1997). Repression of muscle-specific gene activation by the murine Twist protein. Exp Cell Res 232: 295-303. (Pubitemid 27194042)
16. Herynk MH, Fuqua SA. (2004). Estrogen receptor mutations in human disease. Endocr Rev 25: 869-898. (Pubitemid 39657771)
17. Herynk MH, Fuqua SA. (2007). Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 608: 130-143.
18. Mironchik Y, Winnard Jr PT, Vesuna F, Kato Y, Wildes F, Pathak AP et al. (2005). Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65: 10801-10809. (Pubitemid 41715228)
19. Morisset M, Capony F, Rochefort H. (1986). Processing and estrogen regulation of the 52-kilodalton protein inside MCF7 breast cancer cells. Endocrinology 119: 2773-2782. (Pubitemid 17193149)
20. Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson PH. (1997). Estrogen receptor variants and mutations. J Steroid Biochem Mol Biol 62: 363-372. (Pubitemid 28012863)
21. Murre C, McCaw PS, Baltimore D. (1989). A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56: 777-783. (Pubitemid 19082513)
22. O'Doherty AM, Church SW, Russell SE, Nelson J, Hickey I. (2002). Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer 86: 282-284. (Pubitemid 34185159)
23. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. (2001). Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15: 1344-1359. (Pubitemid 32703482)
24. Osborne C, Tripathy D. (2005). Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med 56: 103-116. (Pubitemid 40299776)
25. Osborne CK. (1998). Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238. (Pubitemid 29054556)
26. Osborne CK, Schiff R. (2005). Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol 95: 183-187. (Pubitemid 41137309)
27. Osborne CK, Wakeling A, Nicholson RI. (2004). Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1): S2-S6. (Pubitemid 38482618)
28. Osborne CK, Zhao H, Fuqua SA. (2000). Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172-3186.
29. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. (1994). Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555. (Pubitemid 24173735)
30. Pilat MJ, Schwab ED, Yao KL, Pienta KJ. (1998). Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Anticancer Res 18: 2575-2582. (Pubitemid 28386553)
31. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD et al. (1995). Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87: 446-451.
32. Rose CS, Malcolm S. (1997). A TWIST in development. Trends Genet 13: 384-387. (Pubitemid 127739569)
33. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M et al. (2005). Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1): 10-20.
34. Sengupta K, Banerjee S, Saxena N, Banerjee SK. (2003). Estradiolinduced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. Int J Oncol 22: 609-614.
35. Stasinopoulos IA, Mironchik Y, Raman A, Wildes F, Winnard Jr P, Raman V. (2005). HOXA5-twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem 280: 2294-2299.
36. Vesuna F, Lisok A, Kimble B, Raman V. (2009). Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11: 1318-1328.
37. Vesuna F, van Diest P, Chen JH, Raman V. (2008). Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367: 235-241.
38. Vesuna F, Winnard Jr P, Glackin C, Raman V. (2006). Twist overexpression promotes chromosomal instability in the breast cancer cell line MCF-7. Cancer Genet Cytogenet 167: 189-191. (Pubitemid 44226339)
39. Vesuna F, Winnard Jr P, Raman V. (2005). Enhanced green fluorescent protein as an alternative control reporter to Renilla luciferase. Anal Biochem 342: 345-347. (Pubitemid 40884586)
40. Yan L, Yang X, Davidson NE. (2001). Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 6: 183-192.